Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States

被引:9
|
作者
Michailidou, Despina [1 ,2 ]
Zhang, Tianyu [3 ]
Stamatis, Pavlos [4 ]
Ng, Bernard [1 ,2 ]
机构
[1] Univ Washington, Dept Med, Div Rheumatol, 1959 Pacific St, Seattle, WA 98195 USA
[2] VA Puget Sound Healthcare Syst, Rheumatol Sect, Seattle, WA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Lund Univ, Dept Clin Sci Lund, Rheumatol, Lund, Sweden
关键词
central retinal artery occlusion; central retinal venous occlusion; giant cell arteritis; osteoarthritis; polymyalgia rheumatica; thromboembolism; CHARLSON COMORBIDITY INDEX; PULMONARY-EMBOLISM; ISCHEMIC COMPLICATIONS; EPIDEMIOLOGY; PREVALENCE; SPECTRUM; DISEASE; TRENDS; SERIES;
D O I
10.1111/joim.13446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are systemic inflammatory diseases that primarily affect elderly women. Objectives To compare the risk of thromboembolic events and retinal vascular occlusions in GCA and/or PMR with that in osteoarthritis (OA), evaluating a veteran-based population. Methods A total of 1535 patients with GCA, 10,265 with PMR, and 1203 with overlapping disease, as well as 39,009 age- and sex-matched patients with OA were identified in this retrospective study. The incidence rate ratios (IRRs) of pulmonary embolism (PE), deep venous thrombosis (DVT), arterial thromboembolism, central retinal artery occlusion, and central retinal vein occlusion were calculated and examined over time. The cumulative incidence was plotted and hazard ratios (HRs) of thromboembolic events were calculated, adjusting for independent risk factors of thromboembolism. Results Patients with GCA and overlapping disease exhibited higher IRRs for all thromboembolic events compared to patients with OA. Patients with GCA had a higher risk of developing DVT and retinal vascular occlusions than those with overlapping disease (HR: 2.01, 95% confidence interval [CI]: 1.35-2.99, p < 0.001; HR: 2.37, 95% CI: 1.23-4.53, p = 0.009, respectively) or PMR alone (HR: 1.89, 95% CI: 1.50-2.41, p < 0.001; HR: 4.68, 95% CI: 3.10-7.07, p < 0.001, respectively). Patients with GCA had a higher risk of developing PE than those with PMR (HR: 1.55, 95% CI: 1.1-2.18, p = 0.01). Conclusion The risk of thromboembolic events differs between GCA, PMR, and overlapping diseases. Our findings may help predict the risk of thromboembolic events based on disease phenotype.
引用
收藏
页码:665 / 675
页数:11
相关论文
共 50 条
  • [31] Is there seasonal variation in the onset of symptoms for polymyalgia rheumatica and giant cell arteritis? A community based study.
    Pullman-Mooar, S
    Gordon, GV
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S365 - S365
  • [32] Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica
    Moreel, Lien
    Betrains, Albrecht
    Boeckxstaens, Lennert
    Molenberghs, Geert
    Van Laere, Koen
    De Langhe, Ellen
    Vanderschueren, Steven
    Blockmans, Daniel
    [J]. RHEUMATOLOGY, 2024,
  • [33] STEROID TREATMENT MAY IMPROVE ARTERIAL STIFFNESS IN PATIENTSWITH POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: A PROSPECTIVE COHORT STUDY
    Emamifar, Amir
    Ellingsen, Torkell
    Hess, Soren
    Hansen, Per Syrak
    Hansen, Inger Marie Jensen
    Thye-Ronn, Peter
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 427 - 428
  • [34] Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study
    Raheel, Shafay
    Crowson, Cynthia S.
    Matteson, Eric L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [35] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study
    Mettler, Camille
    Jonville-Bera, Annie-Pierre
    Grandvuillemin, Aurelie
    Treluyer, Jean-Marc
    Terrier, Benjamin
    Chouchana, Laurent
    [J]. RHEUMATOLOGY, 2022, 61 (02) : 865 - 867
  • [36] IMPROVED SURVIVAL IN PATIENTS WITH GIANT CELL ARTERITIS: A POPULATION-BASED COHORT STUDY
    Garvey, T.
    Crowson, C. S.
    Koster, M.
    Matteson, E.
    Warrington, K. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1563 - 1563
  • [37] Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in the Spanish population.
    Martinez-Taboada, VM
    Bartolome, MJ
    Mata-Arnaiz, C
    Blanco, R
    Lopez-Hoyos, M
    Corrales, A
    Calvo, J
    Rodriguez-Valverde, V
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S123 - S123
  • [38] The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
    Henningson, Hampus
    Hammar, Bjorn
    Turesson, Carl
    Mohammad, Aladdin
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 913 - 915
  • [39] MORTALITY IN GIANT-CELL ARTERITIS PATIENTS: A NATIONWIDE POPULATION-BASED STUDY
    Ben-Shabat, Niv
    Amital, Howard
    Cohen, Arnon
    Comanesther, Doron
    Tiosano, Shmuel
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 147 - 148
  • [40] Increased risk of venous thromboembolism in patients with granulomatosis with polyangiitis: A population-based study
    Marozoff, Shelby
    Mai, Alice
    Dehghan, Natasha
    Sayre, Eric C.
    Choi, Hyon K.
    Avina-Zubieta, J. Antonio
    [J]. PLOS ONE, 2022, 17 (06):